Synergistic effects between intrathecal clonidine and neostigmine in the formalin test. by Yoon, M. H. et al.
INTRODUCTION
Spinal administration of alpha-2 agonists and cholines-
terase inhibitors produces a behavioral analgesia in thermal
nociceptive test and formalin test (1-3). This fact implies
that these two drugs may modulate both acute noxious state
and the facilitated state which occurs secondary to the per-
sistent afferent input generated by a tissue injury. Biochem-
ically, intrathecal alpha-2 agonists stimulate norepinephrine
release from the spinal cord dorsal horn (4), and cholines-
terase inhibitors inhibit the breakdown of spinally released
acetylcholine and increase the aceytylcholine concentration
in cerebrospinal fluid (5). Anatomical studies have con-
firmed the localization of alpha-2 adrenergic and choliner-
gic ligand binding in the spinal cord dorsal horn (6, 7).
Therefore, it appears that these drugs exert their antinoci-
ceptive effect by mimicking the action of spinally released
norepinephrine or acetylcholine, which acted on spinal
alpha-2 adrenoceptors or cholinergic receptors, respectively.
Several lines of evidence suggest spinal pharmacologic
interactions between alpha-2 agonists and cholinesterase
inhibitors in acute noxious stimuli. An additive antinoci-
ceptive interaction is found between intrathecal clonidine
and physostigmine in the tail immersion test and the anti-
nociceptive effect of clonidine is attenuated by muscarinic
antagonist (8). On the other hand, spinal coadministration
of clonidine and neostigmine reveals a synergistic antinoci-
ceptive interaction in the thermal nociceptive test and the
antinociception of clonidine is reversed by neither mus-
carinic nor nicotinic antagonists (9). Meanwhile the charac-
teristics of a spinal interaction between an adrenergic sys-
tem and a cholinergic system on the facilitated state have
not definitely established. 
Therefore, we sought to investigate the pharmacologic
properties of spinal alpha-2 agonist, clonidine and spinal
cholinesterase inhibitor, neostigmine and determine the
nature of interaction between these two drugs in rats on a
model of facilitated processing, the formalin test. 
MATERIALS AND METHODS
All studies were conducted according to a protocol appro-
ved by the Institutional Animal Care Committee, Research
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Synergistic Effects Between Intrathecal Clonidine and Neostigmine in 
the Formalin Test
Spinal alpha-2 adrenoceptors and cholinergic receptors are involved in the regu-
lation of acute nociception and the facilitated processing. The aim of this study
was to examine the pharmacological effect of an intrathecal alpha-2 agonist and
a cholinesterase inhibitor on the facilitated pain model induced by formalin injec-
tion and to determine the nature of drug interaction using an isobolographic
analysis. Both intrathecal clonidine and neostigmine dose-dependently sup-
pressed the flinching during phase 1 and phase 2. Intrathecal pretreatment with
atropine reversed the antinociceptive effects of clonidine and neostigmine in
both phases. Pretreatment with intrathecal yohimbine attenuated the effect of
clonidine. The antinociception of clonidine and neostigmine was not reversed by
mecamylamine. Isobolographic analysis showed that intrathecal clonidine and
neostigmine acted synergistically in both phase 1 and 2. Intrathecal pretreat-
ment with atropine and yohimbine antagonized the effect of the mixture of cloni-
dine and neostigmine in both phases, but no antagonism was observed with
mecamylamine pretreatment. These data indicate that spinal clonidine and
neostigmine are effective to counteract the facilitated state evoked formalin stim-
ulus, and these two drugs interact in a synergistic fashion. In addition, the anal-
gesic action of intrathecal clonidine is mediated by spinal muscarinic receptors
as well as alpha-2 adrenoceptors. 
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Male Sprague-Dawley rats (250-300 g) were kept in group
cages with two or three rats and maintained on a 12 hr
night/day cycle with access to food and water at all times.
Chronic intrathecal catheters were implanted according
to a modification of the method described by Yaksh and
Rudy (10). Briefly, the rats were placed in a stereotaxic head
holder during enflurane anesthesia. A polyethylene (PE-10)
catheter was advanced 8.5 cm caudally through an incision
in the atlantooccipital membrane to the level of the lumbar
enlargement. The exposed end of the catheter was tunneled
subcutaneously and externalized on the top of the skull and
plugged with a piece of steel wire. The skin was closed with
3-0 silk sutures. Rats showing motor dysfunction postoper-
atively were sacrificed. After surgery, rats were housed in
the individual cages and allowed to recover for 4-5 days.
The following drugs were used in this study: clonidine
hydrochloride (Sigma Chemical Co., St. Louis, MO, U.S.A.),
neostigmine bromide (Research Biochemical Internationals
[RBI], Natick, MA, U.S.A.), atropine sulfate (RBI), yohim-
bine hydrochloride (Sigma), and mecamylamine hydrochlo-
ride (RBI). Yohimbine was prepared by dissolving the drug
in distilled water and other drugs were dissolved in physio-
logic saline. Intrathecal delivery of these drugs was per-
formed using a hand-driven, gear-operated syringe pump.
All drugs were administered in a volume of 10  L solution,
followed by an additional 10  L of saline to flush the
catheter. Physiologic saline was injected for control experi-
ments.
The formalin test was used as a nociceptive test. 50  L of
5% formalin solution was injected subcutaneously into the
plantar surface of the hindpaw with a 30-gauge needle.
Pain behavior was quantified by periodically counting the
incidence of flinching/shaking of the injected paw. The
flinches were counted for 5 min periods from 0-60 min.
Two phases of spontaneous flinching were observed after the
formalin injection. The interval from 0-10 min was defined
as phase 1 of the formalin test and the interval 10-60 min
was defined as phase 2. After experiments, the rats were
immediately sacrificed.
The first series of experiments were performed to deter-
mine the time course and dose-dependency of antinocicep-
tive effects of intrathecally administered clonidine (0.3, 1,
3, 10  g) and neostigmine (0.1, 0.3, 1, 3  g ). Two drugs
were administered 10 min before formalin injection. To
determine the antagonistic properties for each agent, alpha-
2 (yohimbine 30  g), muscarinic (atropine 15  g), and
nicotinic (mecamylamine 15  g) antagonists were adminis-
tered 10 min before intrathecal delivery of clonidine and
neostigmine. Formalin test was performed 10 min after
intrathecal administration of clonidine and neostigmine. To
define the nature of interaction between clonidine and neos-
tigmine at the spinal level, an isobolographic analysis was
done (11). At first, each ED50 value (effective dose produc-
ing a 50% reduction of control formalin response) was
determined from the dose-response curves of each of two
agents. Next, the respective ED50 values of each drug were
coadministered based on the fractions of this dose combina-
tion. Thus, clonidine ED50+neostigmine ED50, (clonidine
ED50+neostigmine ED50)/2, (clonidine ED50+neostigmine
ED50)/4 and (clonidine ED50+neostigmine ED50)/8 were
injected. From the dose-response curves of the combined
drugs, the ED50 values of the mixture were calculated and
these dose combinations were used for plotting the isobolo-
gram. In this study, the ED50 values were determined sepa-
rately in two phases in the formalin test. The isobologram
was constructed by plotting the ED50 values of the single
agents on the X and Y axes, respectively. The theoretical
additive dose combination was calculated. From the vari-
ance of the total dose, individual variances for the agents in
the combination were obtained. Furthermore, to describe
the magnitude of the interaction, a total fraction value was
calculated. 
Total ED50 of drug 1 combined with drug 2
fraction value =
ED50 for drug 1 given alone
ED50 of drug 2 combined with drug 1
+
ED50 for drug 2 given alone
The fractional values indicate what portion of the single
ED50 value was accounted for by the corresponding ED50
value for the combination. Values near 1 indicate additive
interaction, values greater than 1 imply an antagonistic inter-
action and values less than 1 indicate a synergistic interac-
tion. The antagonism of the mixture of intrathecal cloni-
dine and neostigmine was evaluated. Yohimbine (30  g),
atropine (15  g), and mecamylamine (15  g) were adminis-
tered intrathecally 10 min before intrathecal mixture (cloni-
dine ED50+neostigmine ED50) injection, respectively. For-
malin was injected 10 min after the administration of
intrathecal mixture.
All data are expressed as means±SEM. The time
response data are presented as the number of flinches per 5
min. The dose-response data are presented as the sum of
flinches in each phase. To obtain ED50, the flinches were
converted to percentage maximal possible effect (%MPE).
Sum of phase 1 (2) count with drug
%MPE = × 100  
Sum of control phase 1 (2) count
Dose-response data were analyzed by one-way analysis of
variance (ANOVA) with Bonferroni for post hoc. The dose-
response lines were fitted using least-squares linear regres-
sion and ED50 and its 95% confidence intervals were calcu-
lated according to the method described by Tallarida and
Murray (12).
The difference between theoretical ED50 and experimen-500 M.H. Yoon, K.Y. Yoo, C.Y. Jeong
tal ED50 was examined by t-test. The effect of antagonist on
the agonist mixture was analyzed by ANOVA. p<0.05 was
considered statistically significant.
RESULTS
No motor impairment was observed in rats after intrathe-
cal administration of clonidine and neostigmine. Some rats
receiving intrathecal clonidine and atropine showed urina-
tion or vocalization. Neither yohimbine nor mecamylamine
affected general behavior or motor function.
Subcutaneous formalin injection resulted in a biphasic
flinching response of the injected paw (Fig. 1). Intrathecal
administration of clonidine and neostigmine produced a
dose-dependent suppression of the flinching during phase 1
and phase 2 in the formalin test (Fig. 2). The ED50 of cloni-
dine and neostigmine alone were 1.8 and 0.7  g in phase 1
and 1.6 and 0.43  g in phase 2 (Table 1). Thus, the calcu-
lated dose ratio for clonidine and neostigmine were 2.5:1 in
phase 1 and 3.7:1 in phase 2.
The antinociceptive effect of intrathecal clonidine was antag-
ED50 (95% CI)  g Slope (95% CI)  g ED50 (95% CI)  g Slope (95% CI)  g
Phase 2 Phase 1
Clonidine 1.8 (1.2~2.7) -50.9 (-66.4~-35.5) 1.6 (1.1~2.1) -51.7 (-64.5~-38.9)
Neostigmine 0.72 (0.53~0.98) -51.8 (-64.0~-39.5) 0.43 (0.31~0.58) -52.5 (-64.7~-40.3)
Clonidine# 0.38 (0.32~0.45) -66.0 (-79.2~-52.8) 0.35 (0.29~0.41) -67.6 (-79.7~-55.4)
Dose-Ratio 2.5:1 3.7:1
Total Fraction Value 0.43 0.35
Table 1. Effect of intrathecal clonidine and neostigmine alone or combination in the formalin test
ED50, effective dose resulting in a 50% reduction of control response; CI, confidence intervals; #, the value in the mixture of clonidine and neostig-
mine; Dose-Ratio, a ratio for clonidine and neostigmine
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Fig. 1. Time course effect of intrathecal clonidine and neostigmine on the flinching in the formalin test. The number of flinches per 5 min
is plotted versus time. Each point on the graph represents the mean ±SEM of 5-6 rats.
Fig. 2. Dose-response curves of intrathecal clonidine and neostigmine on the flinching during phase 1 and phase 2 in the formalin test.
Data are expressed as the sum of flinches versus log dose in micrograms. Each point on the graph represents the mean±SEM of 5-6
rats. Intrathecal clonidine and neostigmine resulted in a dose-dependent suppression of the flinching in both phases. 
� p<0.01, 
� p<0.001
compared with control.
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onized by pretreatment with intrathecal atropine and yohim-
bine during phase 1 and phase 2 in the formalin test (Fig. 3).
Pretreatment with intrathecal atropine reversed the anti-
nociception of intrathecal neostigmine in both phases, but
intrathecal yohimbine was ineffective in antagonizing the
effect of neostigmine (Fig. 4).
As shown in Fig. 3 and 4, intrathecal mecamylamine did
not affect the antinociceptive effect of intrathecal clonidine
and neostigmine. Isobolographic analysis revealed a syner-
gistic interaction between intrathecal clonidine and neostig-
mine in two phases of the formalin test (Fig. 5).
The experimental ED50 was significantly less than the cal-
culated ED50. Thus, the ED50 of the clonidine-neostigmine
mixture was 0.38  g in phase 1 and 0.35  g in phase 2
(Table 1). Each total fraction value of phase 1 and phase 2
was 0.43 and 0.35, respectively, which corresponded to the
synergistic interaction. Intrathecal atropine and yohimbine
reversed the effect of the mixture (clonidine ED50+neostig-
mine ED50), while mecamylamine did not show such antag-
onism (Fig. 6).
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Fig. 3. Antagonistic effect of atropine (AT, 15  g), yohimbine (YO, 30  g), and mecamylamine (ME, 15  g) on the antinociception of
clonidine (CLO, 10  g) in the formalin test. AT, YO and ME were delivered intrathecally either 10 min before CLO administration, and for-
malin was injected 10 min later. Each bar expressed as the sum of flinches on the graph represents the mean ±SEM of 5-6 rats.
Intrathecal atropine and yohimbine reverse the effect of clonidine in both phases. 
� p<0.001 compared with control (C).
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Fig. 4. Antagonistic effect of atropine (AT, 15  g), yohimbine (YO, 30  g), and mecamylamine (ME, 15  g) on the antinociception of
clonidine (CLO, 10  g) in the formalin test. AT, YO and ME were delivered intrathecally either 10 min before NEO administration, and for-
malin was injected 10 min later. Each bar expressed as the sum of flinches on the graph represents the mean ±SEM of 5-6 rats.
Intrathecal atropine reverses the effect of neostigmine in both phases. 
� p<0.001 compared with control (C).
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DISCUSSION
Rats injected with formalin into the paw showed the
characteristic biphasic pain behavior, a flinching response.
Mechanistically, phase 1 flinching seems to result from the
immediate and intense increase of primary afferent activity.
On the other hand, phase 2 response mirrors the activation
of wide dynamic range dorsal horn neurons with a very low
level of ongoing activity of primary afferents (13). Thus, the
neural process of each phase is fundamentally different. Par-
ticularly, phase 2 reflects a facilitated state that occurs sec-
ondary to the persistent afferent input generated by a local
tissue injury. 
Formalin stimulus evokes a spinal release of glutamate and
substance-P, through their respective N-methyl D-aspartate
and neurokinin-1 receptors, which initiates a cascade,
including an increase of intracellular calcium and the acti-
vation of kinases. Subsequent complex cascade leads to a
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Fig. 5. Isobologram for the interaction between intrathecal clonidine and neostigmine in the formalin test. The straight line connecting the
single drug ED50 points is the theoretical additive line, and the point on this line is the theoretical ED50 (A). The heavy lines on the axes
represent the SEM of ED50. The experimental ED50 point (B) for the mixture lies below the theoretical additive point in both phases, indi-
cating a synergistic interaction. Each point on the graph represents the mean ±SEM of 5-6 rats.
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Fig. 6. Antagonistic effect of atropine (AT, 15  g), yohimbine (YO, 30  g), and mecamylamine (ME, 15  g) on the antinociception of mix-
ture of clonidine and neostigmine (M, ED50) in the formalin test. AT, YO and ME were delivered intrathecally either 10 min before the mix-
ture administration, and formalin was injected 10 min later. Each bar expressed as the sum of flinches on the graph represents the mean
±SEM of 5-6 rats. Intrathecal atropine and yohimbine reverse the effect of mixture in both phases. 
� p<0.001 compared with control (C).
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state of facilitation (14).
In the current study, intrathecal clonidine and neostig-
mine resulted in the antinociception during phase 1 and
phase 2 in the formalin test. This observation implicates
that clonidine and neostigmine are effective for the facilitat-
ed state as well as acute nociception at the spinal level.
Autoradiographic studies have demonstrated a high density
of alpha-2 adrenoceptors, muscarinic and nicotinic receptors
in lamina I and II of the dorsal horn, areas important in
nociceptive processing (6, 7). Rhizotomies have been shown
to reduce alpha-2 and muscarinic binding in the spinal dor-
sal horn (15, 16). Previous studies showed that intrathecal
administration of clonidine and neostigmine increases the
concentration of cerebrospinal norepinephrine or acetyl-
choline (4, 5).
These findings jointly suggest that intrathecal clonidine
and neostigmine increase the level of spinal norepinephrine
or acetylcholine, thereby producing an antinociceptive effect,
which is mediated by the spinal alpha-2 adrenoceptor or
cholinergic receptor, in acute noxious stimuli and the facilitat-
ed state.
Another possibility that explains this antinociception of
intrathecal clonidine and neostigmine would be the role of
the descending inhibitory pathway. Noxious stimulation is
able to activate the intrinsic pain inhibitory system, thereby
increasing the release of inhibitory neurotransmitters such
as norepinephrine and acetylcholine (17, 18). In a micro-
dialysis study, Eisenach et al. (19) confirmed that cere-
brospinal concentration of norepinephrine and acetylcholine
increased during acute pain. Accordingly, the activation of
the descending inhibitory pathway by a formalin stimulus
may increase the level of spinal norepinephrine and acetyl-
choline, thus enhancing the antinociceptive effect of intrathe-
cal clonidine and neostigmine.
In the present study, the antinociceptive effect of the
intrathecal clonidine was antagonized by not only intrathe-
cal alpha-2 antagonist but also intrathecal muscarinic
antagonist during phase 1 and phase 2 in the formalin test.
These results are in accord with the previous findings of
Gordh et al. (8) who have shown an attenuation of cloni-
dine-induced antinociception by intrathecal atropine. These
findings imply that the antinociceptive action of intrathecal
clonidine is mediated by spinal muscarinic receptor as well
as alpha-2 adrenoceptor. However, contrary to our findings,
others have not observed such antagonism (9, 20). Although
the reasons for these differences among experiments are
unclear, the facts obtained from our data suggest a possibili-
ty of neuronal connection in the spinal cord. Detweiler et al.
(20) suggested that adrenergic neurons may cause presynap-
tic excitation of muscarinic neuron, not vice versa. This sug-
gestion is supported by our data because the antinocicep-
tion of clonidine was reversed by atropine, but that of
neostigmine was not reversed by yohimbine. Additionally,
in this study, the antinociception of intrathecal clonidine
and neostigmine was not reversed by intrathecal nicotinic
antagonist, which suggests that spinal nicotinic receptor
may not be involved in the analgesic action of intrathecal
clonidine and neostigmine in acute nociception and the
facilitated state. Furthermore, intrathecal nicotinic agonist,
epibatidine, does not alter pain behaviors of the formalin
test (3). However, the antiallodynic effect of intrathecal
clonidine on neuropathic pain is attenuated by spinal mus-
caric and nicotinic antagonists (21). Therefore, further eval-
uation of spinal interaction among adrenergic, muscarinic,
and nicotinic systems will be necessary.
Isobolographic analysis used here demonstrated the syn-
ergistic interaction between intrathecal clonidine and neos-
tigmine in both phases. Previous studies showed that the
antinociceptive effect of intrathecal clonidine was additively
enhanced by intrathecal physostigmine and neostigmine in
acute nociceptive situations (8, 20). On the other hand, the
coadministration of intrathecal clonidine and neostigmine
or edrophonium exhibited a synergistic effect in acute ther-
mal stimulus (9). Our results suggest that the synergism
between clonidine and neostigmine at the spinal level occurs
in the facilitated state as well as in acute nociception. Sever-
al explanations would be possible for this synergistic inter-
action. First, agents may interact by changing the kinetic
variables of each other at the target site. Second, functional
interaction may result from distinct drug effects at separate
anatomic sites that may act independently as well as togeth-
er to inhibit spinal nociceptive processing (22). It has been
known that an alpha-2 agonist has a presynaptic inhibitory
effect on the terminals of the primary afferent in the spinal
cord and decreases the release of excitatory neurotransmit-
ters such as substance-P and calcitonin gene-related peptide
(CGRP) (23). Postsynaptically, it inhibits the activity of
wide dynamic range dorsal horn neurons, which transmit
nociceptive information (24). Further, histochemical studies
have shown that the choline acetyltransferase positive cells
are distributed in dendrites and axons within the substantia
gelatinosa of the dorsal horn (25). Immunopositive varicosi-
ties are found pre- and post-synaptic to the central varicosi-
ties associated with large and small axons. These observa-
tions suggest that spinal cholinesterase inhibitor may regu-
late the nociceptive transmission and processing by pre- and
post-synaptic mechanisms. Therefore, simultaneous engage-
ment of pre- and post-synaptic mechanisms may augment
the antinociceptive action produced by either drug acting at
one site independently (26). Third, spinal clonidine is a
cholinesterase inhibitor (27) and increases acetylcholine
concentration in cerebrospinal fluid (28). Hence, the coad-
ministration of clonidine and neostigmine increases acetyl-
choline more than either drug alone and may lead to a syn-
ergism. Finally, norepinephrine has been reported to inhibit
cholinesterase activity (29). This action would further
increase the acetylcholine level and promote antinociception
after concurrent delivery of clonidine and neostigmine. In conclusion, the present study demonstrated that int-
rathecal clonidine and neostigmine attenuate both acute
noxious stimulus and the facilitated state generated by for-
malin injection, and these two drugs act synergistically. The
spinal alapha-2 and partly muscarinic receptor system is
associated with the intrathecal clonidine-induced antinoci-
ception. However that of intrathecal neostigmine matched
to only spinal muscarinic receptor system. 
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